Carl Dambkowski
Known title: DirectorCIK: 0001983476
Associated companies
Transaction History
| ORKA | ▼ Sell | Open Market | 12,583 | $882K | 6/12/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 22,417 | $1.6M | 6/11/2026 | View on chart |
| ORKA | ▲ Buy | Option Exercise | 38,689 | $265K | 5/21/2026 | View on chart |
| ORKA | ▲ Buy | Option Exercise | 11,904 | $93K | 5/21/2026 | View on chart |
| ORKA | ▲ Buy | Option Exercise | 11,667 | $137K | 5/21/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 38,318 | $2.2M | 5/21/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 53,447 | $3.2M | 5/21/2026 | View on chart |
| ORKA | ▼ Sell | Open Market | 13,235 | $794K | 5/21/2026 | View on chart |
| ORKA | ▼ Sell | Other | 116,483 | $0 | 1/23/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
HC Wainwright Reiterates $120 Target on Oruka
HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.
HC Wainwright Reiterates $120 Target on Oruka. HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.